PG110 ONCE DAILY MESALAZINE FOR MAINTAINING REMISSION IS COST-SAVING COMPARED TO TWICE DAILY MESALAZINE- AN ECONOMIC EVALUATION BASED ON THE PODIUM RANDOMISED CONTROLLED TRIAL
Abstract
Authors
M Connolly SK Nielsen CJ Currie CD Poole